BIOCRYST PHARMACEUTICALS INC (BCRX)

US09058V1035 - Common Stock

4.41  -0.02 (-0.45%)

After market: 4.41 0 (0%)

Fundamental Rating

2

BCRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. BCRX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, BCRX is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

BCRX had negative earnings in the past year.
In the past year BCRX has reported a negative cash flow from operations.
BCRX had negative earnings in each of the past 5 years.
In the past 5 years BCRX always reported negative operating cash flow.

1.2 Ratios

BCRX has a Return On Assets of -43.82%. This is comparable to the rest of the industry: BCRX outperforms 57.02% of its industry peers.
Industry RankSector Rank
ROA -43.82%
ROE N/A
ROIC N/A
ROA(3y)-40.02%
ROA(5y)-47.36%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 98.59%, BCRX belongs to the best of the industry, outperforming 98.80% of the companies in the same industry.
In the last couple of years the Gross Margin of BCRX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BCRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y0.21%

2

2. Health

2.1 Basic Checks

BCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BCRX has more shares outstanding
The number of shares outstanding for BCRX has been increased compared to 5 years ago.
Compared to 1 year ago, BCRX has a worse debt to assets ratio.

2.2 Solvency

BCRX has an Altman-Z score of -3.21. This is a bad value and indicates that BCRX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.21, BCRX perfoms like the industry average, outperforming 44.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.21
ROIC/WACCN/A
WACC6%

2.3 Liquidity

A Current Ratio of 3.31 indicates that BCRX has no problem at all paying its short term obligations.
BCRX's Current ratio of 3.31 is on the low side compared to the rest of the industry. BCRX is outperformed by 63.18% of its industry peers.
BCRX has a Quick Ratio of 3.12. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.
BCRX has a worse Quick ratio (3.12) than 63.87% of its industry peers.
Industry RankSector Rank
Current Ratio 3.31
Quick Ratio 3.12

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.56% over the past year.
Looking at the last year, BCRX shows a very strong growth in Revenue. The Revenue has grown by 22.37%.
The Revenue has been growing by 74.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)25.56%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q26.32%
Revenue 1Y (TTM)22.37%
Revenue growth 3Y165.04%
Revenue growth 5Y74.13%
Revenue growth Q2Q17.41%

3.2 Future

BCRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.49% yearly.
Based on estimates for the next years, BCRX will show a quite strong growth in Revenue. The Revenue will grow by 19.21% on average per year.
EPS Next Y37%
EPS Next 2Y28.34%
EPS Next 3Y26.5%
EPS Next 5Y26.49%
Revenue Next Year20.71%
Revenue Next 2Y20.47%
Revenue Next 3Y19.77%
Revenue Next 5Y19.21%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

BCRX's earnings are expected to grow with 26.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.34%
EPS Next 3Y26.5%

0

5. Dividend

5.1 Amount

BCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (4/22/2024, 5:50:50 PM)

After market: 4.41 0 (0%)

4.41

-0.02 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap909.12M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.82%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 98.59%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.31
Quick Ratio 3.12
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)25.56%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y37%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.37%
Revenue growth 3Y165.04%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y